Response to “Risperidone and sulpiride: Brands vs generics”

We are grateful to Professor Chittaranjan Andrade for the two opinions he raised about our work (Andreade, 2017). The first is that the daily doses used in this study were not previously observed in a randomized clinical trial. As a result, he suggests that the differences in doses of brand-name and generic antipsychotic drugs may be influenced by patients' or clinicians' willingness. The dosing strategies may in fact be influenced by various factors in realistic settings, such as treatment response, side effects, patients' or clinicians' confidence, and therapeutic adherence.
Source: Schizophrenia Research - Category: Psychiatry Authors: Source Type: research